Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Shikonin-mediated PD-L1 degradation suppresses immune evasion in pancreatic cancer by inhibiting NF-κB/STAT3 and NF-κB/CSN5 signaling pathways
Zhiyan Ruan, Minhua Liang, Ling Shang, et al.
Pancreatology (2021) Vol. 21, Iss. 3, pp. 630-641
Closed Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Promising Nanomedicines of Shikonin for Cancer Therapy
Chunmei Yan, Qiuxia Li, Qiang Sun, et al.
International Journal of Nanomedicine (2023) Vol. Volume 18, pp. 1195-1218
Open Access | Times Cited: 37
PD-L1: expression regulation
Yujie Zhou, Guoli Li, Jiyin Wang, et al.
Blood Science (2023) Vol. 5, Iss. 2, pp. 77-91
Open Access | Times Cited: 30
Challenges Coexist with Opportunities: Spatial Heterogeneity Expression of PD‐L1 in Cancer Therapy
Yazhen Wang, Zhou Yang, Lianyi Yang, et al.
Advanced Science (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 24
Shikonin Inhibits Tumor Growth of ESCC by suppressing PKM2 mediated Aerobic Glycolysis and STAT3 Phosphorylation
Qiqi Zhang, Qing Liu, Shutao Zheng, et al.
Journal of Cancer (2021) Vol. 12, Iss. 16, pp. 4830-4840
Open Access | Times Cited: 44
Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy
Sepideh Mirzaei, Mohammad Gholami, Hui Li Ang, et al.
Cells (2021) Vol. 10, Iss. 12, pp. 3348-3348
Open Access | Times Cited: 44
Natural products and their derivatives as immune check point inhibitors: Targeting cytokine/chemokine signalling in cancer
Meenakshi Gupta, Kumari Chandan, Maryam Sarwat
Seminars in Cancer Biology (2022) Vol. 86, pp. 214-232
Closed Access | Times Cited: 36
Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert
Xiaoqi Li, Mansi Gulati, Alaina C. Larson, et al.
Seminars in Cancer Biology (2022) Vol. 86, pp. 14-27
Open Access | Times Cited: 34
Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action
Mehdi Valipour
European Journal of Medicinal Chemistry (2022) Vol. 235, pp. 114314-114314
Closed Access | Times Cited: 31
Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy
Chong Feng, Lening Zhang, Xin Chang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 19
Targeting CD8+ T cells with natural products for tumor therapy: Revealing insights into the mechanisms
Yuke Wang, Yan Zeng, Wenyong Yang, et al.
Phytomedicine (2024) Vol. 129, pp. 155608-155608
Closed Access | Times Cited: 8
Recent advances and mechanisms of action of PD-L1 degraders as potential therapeutic agents
Feng Zhang, Ruiya Jiang, Shishi Sun, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116267-116267
Closed Access | Times Cited: 6
STAT3 Inhibitors: A Novel Insight for Anticancer Therapy of Pancreatic Cancer
Xin Li, Wenkai Jiang, Shi Dong, et al.
Biomolecules (2022) Vol. 12, Iss. 10, pp. 1450-1450
Open Access | Times Cited: 24
Pharmacological and analytical aspects of alkannin/shikonin and their derivatives: An update from 2008 to 2022
Kirandeep Kaur, Rashi Sharma, Atamjit Singh, et al.
Chinese Herbal Medicines (2022) Vol. 14, Iss. 4, pp. 511-527
Open Access | Times Cited: 23
Deubiquitinating enzymes: potential regulators of the tumor microenvironment and implications for immune evasion
Sheng‐Kai Hsu, Chon‐Kit Chou, I‐Ling Lin, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 5
Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3/Jab1-PD-L1 signalling
Ping Zhu, Zhengxin Jin, Guiyu Kang, et al.
Cell Communication and Signaling (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 21
Natural products target glycolysis in liver disease
Shenghao Li, Liyuan Hao, Xiaoyu Hu
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 12
Modulation of N-glycosylation in the PD-1: PD-L1 axis as a strategy to enhance cancer immunotherapies
Monika Granica, Gustaw Laskowski, Paweł Link-Lenczowski, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025), pp. 189274-189274
Open Access
Inflammation, microbiota, and pancreatic cancer
Xiaoliang Chen, F.W. Sun, Xuqin Wang, et al.
Cancer Cell International (2025) Vol. 25, Iss. 1
Open Access
Perspectives on the α5 nicotinic acetylcholine receptor in lung cancer progression
Jiaying Cai, Jingting Wang, Z. Wang, et al.
Frontiers in Cell and Developmental Biology (2025) Vol. 13
Open Access
Shikonin induced Apoptosis Mediated by Endoplasmic Reticulum Stress in Colorectal Cancer Cells
Hui Qi, Xing Zhang, Huanhuan Liu, et al.
Journal of Cancer (2021) Vol. 13, Iss. 1, pp. 243-252
Open Access | Times Cited: 21
Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy
Peng Ding, Z. Ma, Yizeng Fan, et al.
Genes & Diseases (2022) Vol. 10, Iss. 3, pp. 848-863
Open Access | Times Cited: 16
Novel shikonin derivatives suppress cell proliferation, migration and induce apoptosis in human triple-negative breast cancer cells via regulating PDK1/PDHC axis
Qingqing Chen, Hongwei Han, Faxiang Lin, et al.
Life Sciences (2022) Vol. 310, pp. 121077-121077
Closed Access | Times Cited: 15
Effects of small molecules on neurogenesis: Neuronal proliferation and differentiation
Michał K. Jastrzębski, Piotr Wójcik, Piotr Stępnicki, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 1, pp. 20-37
Open Access | Times Cited: 9
Natural Compound Shikonin Is a Novel PAK1 Inhibitor and Enhances Efficacy of Chemotherapy against Pancreatic Cancer Cells
Wenjing Ji, Xiaoyan Sun, Yang Gao, et al.
Molecules (2022) Vol. 27, Iss. 9, pp. 2747-2747
Open Access | Times Cited: 14
Shikonin Derivatives Inhibit Inflammation Processes and Modulate MAPK Signaling in Human Healthy and Osteoarthritis Chondrocytes
Birgit Lohberger, Heike Kaltenegger, Nicole Eck, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 6, pp. 3396-3396
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top